Professional background

Dr Hiley is an Associate Professor with tenure in Radiation Oncology at UCL and an Honorary Consultant Clinical Oncologist at UCLH.

He graduated with honours from the University in Manchester in 2005. He has trained in Oncology at many centres of excellence both in the UK and aboard. These include the Christie Hospital, the MD Anderson Cancer Centre (Houston, USA), Kings College (NIHR Clinical Lecturer) and the Royal Marsden (NIHR Clinical Fellow). He completed a PhD at the University of London with the Barts Cancer Institute and a postdoctoral research Fellowship the Francis Crick Institute and the UCL Cancer institute.

He became a consultant in 2018 joining the thoracic oncology team at UCLH. In addition, he is the UCLH Lead for Lung Proton Therapy, Deputy Lead of Clinical Trials Theme for the CRUK Lung Cancer Centre of Excellence and NIHR Clinical Research Network Speciality Research Lead Radiotherapy for North London. He heads a research group at the UCL Cancer Institute focused on understanding resistance to radiation therapy.

Dr Hiley specialises in non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy and Stereotactic Radiotherapy (SBRT). Dr Hiley has expertise in treating all sites of metastatic disease (except for brain) with stereotactic radiotherapy including lung, liver, lymph nodes, adrenal glands, spine and other bone sties.

He is the principal investigator and national chief investigator for several academic and commercial clinical trials in lung cancer. He has published in several the world’s leading journals including NEJM, The Lancet, Nature and Cell. He is a member of the expert group which authored the Radiotherapy for Lung Cancer Royal College of Radiologists Consensus Statement.

Research interests

Understanding resistance to radiotherapy and immunotherapy in NSCLC.

Proton therapy

Clinical Trials

Languages spoken

English, French